Company News


This press release is posted as a service by Angioplasty.Org


CYPHER® Sirolimus-Eluting Coronary Stent
Receives FDA Approval for MRI Scans
Immediately Following Implantation

CYPHER® Stent Patients Benefit From Immediate Access to Important MRI Tests, Diagnostics

MIAMI, April 20 -- Cordis Corporation, a Johnson & Johnson company, today announced that the U.S. Food and Drug Administration (FDA) has approved a condition of use for the CYPHER® Sirolimus-eluting Coronary Stent, allowing patients receiving the stent to immediately undergo Magnetic Resonance Imaging (MRI) following implantation. Approval was granted after laboratory studies demonstrated the CYPHER® Stent is MRI-safe.

"With the FDA approval, cardiologists and their patients receiving a CYPHER® Stent can now benefit from important MRI tests and diagnostics immediately following the procedure, further enhancing the overall level and quality of health care for stent patients," said Dennis Donohoe, MD, Worldwide Vice President of Regulatory and Clinical Affairs for Cordis Corporation.

MRI is an important tool for imaging and diagnosing a variety of medical conditions. Due to the use of intense magnetic fields during MRI testing, laboratory studies needed to show that implanted medical devices that contain stainless steel metal, such as stents, are safe and not subject to potential migration and heating. The laboratory studies on the CYPHER® Stent provided the evidence needed for this condition of use. Patients no longer have to wait two months after a procedure with the CYPHER® Stent before undergoing an MRI test.

About the CYPHER® Stent
Developed and manufactured by Cordis Corporation, the CYPHER® Stent is currently available in more than 80 countries and has been used by doctors to treat more than 1 million patients worldwide. With more than 40 clinical trials conducted or in progress worldwide, the CYPHER® Stent remains the most studied drug-eluting stent today with the largest body of clinical evidence demonstrating the long-term safety and efficacy of its drug and polymer. In clinical trials, the CYPHER® Stent has been shown to reduce reblockage in the arteries by more than 90 percent over a conventional bare metal stent. More information about the CYPHER® Stent can be found at http://www.CYPHERusa.com.

About Cordis Corporation
Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in developing and manufacturing interventional vascular technology. Through research, development and innovation, physicians worldwide are better able to treat the millions of patients who suffer from vascular disease. For more information about Cordis, please visit http://www.cordis.com.

*Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including delivery via vascular stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune®. Rapamune is a trademark of Wyeth Pharmaceuticals.

Source: Cordis Corporation

Angioplasty.Org Home •  PatientCenter

this press release is posted as a reader service by Angioplasty.org,
an independent educational health site
which has received support from
Medtronic, Inc., Toshiba America Medical Systems, Volcano Corporation, Terumo Medical Corporation
Cardium Therapeutics, Inc. and Lenox Hill Heart and Vascular Institute of NY
All content, including text, photos and video
©Copyright Venture Digital LLC 1996-2012